Results 141 to 150 of about 82,297 (250)

Trust first, concerns second: An international vignette study of older adults' preferences towards deprescribing statins

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1509-1518, May 2026.
Abstract This study investigated the attitudes and beliefs of older adults towards deprescribing statins in Australia, the United Kingdom and the United States, using an online, vignette‐based study. Presented with a hypothetical scenario in which a general practitioner advised stopping simvastatin, participants rated their level of agreement and ...
Sarah E. Vordenberg, Noelia Dulo, Carissa Bonner, Eliza Ferguson, Vincent D. Marshall, Kristie Rebecca Weir   +5 more
wiley   +1 more source

The impact of generic reference pricing interventions in the statin market [PDF]

The objective of this study was to evaluate the intended and unintended impact on pharmaceutical use and sales of three public financing reforms applied to the prescription of statins: a Spanish generic reference pricing (RP) system for lovastatin and ...
Jaume Puig
core  

APOE genotype and the effect of statins on lipid outcomes: A meta‐analysis

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1268-1286, May 2026.
Aim APOE genotype may affect statin therapy response. We conducted a meta‐analysis to update and quantify this association across various outcomes. Methods We searched seven databases (MEDLINE, Scopus, Web of Science, the Cochrane Library, APA PsycINFO, CINAHL Plus and ClinicalTrials.gov) on 9 May 2024.
Innocent G. Asiimwe, Tsegay Gebru, Andrea L. Jorgensen, Munir Pirmohamed, on behalf of the Multimorbidity Mechanism and Therapeutics Research Collaborative   +4 more
wiley   +1 more source

Mechanotransduction in the Brain: Soliton Theory, Piezo Receptors and MR Elastography in Headache Pathophysiology

Brain and Behavior, Volume 16, Issue 5, May 2026.
ABSTRACT Purpose This narrative review aims to explore how incorporating mechanical and thermal dimensions can complement and extend the classical Hodgkin‐Huxley (HH) model to enrich the understanding of headache and pain pathophysiology. Method This review examines the integration of three distinct concepts with the HH model.
Joan Crespi, Axel Karl Gottfrid Nyman, Erling Tronvik, Lanfranco Pellesi, Igor Petrušić, Tobias Navarro Schröder   +5 more
wiley   +1 more source

PLA2R‐Positive Membranous Nephropathy and AA Amyloidosis in an Ethiopian Patient With Chronic Hepatitis B: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT The coexistence of primary phospholipase A2 receptor positive membranous nephropathy and AA amyloidosis in a patient with chronic hepatitis B is an exceedingly rare triad presenting a profound diagnostic and therapeutic challenge. A 38‐year‐old Ethiopian man with nephrotic syndrome and chronic hepatitis B had dual pathology on renal biopsy ...
Betelhem Abreham, Leja Hamza, Azeb Kebede, Daniel Rebuma Bekele, Zekarias Amdemariam   +4 more
wiley   +1 more source

An Update to the Clinical Pharmacogenetics Implementation Consortium (CPIC) SLCO1B1 Allele Functionality Table Leveraging Evidence from Participants of Predominantly Sub‐Saharan African Ancestry

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1133-1135, May 2026.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has formally updated the SLCO1B1 allele functionality table based on new evidence. Notably, the alleles studied (SLCO1B1 *9, *31, *41) are enriched in the genomes of patients historically excluded from pharmacogenomics research.
Akinyemi Oni‐Orisan, Sook Wah Yee, Tanushree Haldar, Michelle Whirl‐Carrillo, Kelly Caudle, Deepak Voora, Richard B. Kim   +6 more
wiley   +1 more source

Actionable Pharmacogenomics and Essential Medicines: An Analysis of WHO and African Lists for Safer and Efficacious Drug Use

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1371-1381, May 2026.
The World Health Organization Model Essential Medicines List and African national essential medicines lists (EMLs) detail drugs intended to be consistently available within national health systems, thereby supporting clinicians and pharmacists in making evidence‐based treatment decisions.
Tinashe A. Mazhindu, Mohamed Nagy, David Twesigomwe, Gaye Agesa, Janine Scholefield, Collen Masimirembwa   +5 more
wiley   +1 more source

The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics‐Based Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1382-1390, May 2026.
Genetic variation has a significant impact on patients' response to medicines. Variations in important pharmacogenes have been evaluated in several studies and consequently led to international guidelines from clinical pharmacogenomics consortia. However, there are limited examples of these being implemented across the African continent despite the ...
Janine Scholefield, Tinashe A. Mazhindu, Mohamed Nagy, David Twesigomwe, Gaye Agesa, Collen Masimirembwa   +5 more
wiley   +1 more source

Unlocking beta cell health: The clinical potential of extracellular vesicles in type 1 diabetes

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
Extracellular vesicles serve as minimally invasive biomarkers of β‑cell stress and immune dysregulation in T1D. This review highlights the potentials of EVs as a biomarker to improve early detection and disease staging in type 1 diabetes. Abstract Background Type 1 diabetes (T1D) is a lifelong autoimmune disease characterised by progressive immune ...
Nanthini Jayabalan, Flavio Carrion, Kriti Joshi, Tony Huynh, Carlos Salomon   +4 more
wiley   +1 more source

The Effect of Liraglutide on the Hypolipidemic, Anti-Inflammatory, and Antioxidant Properties of Atorvastatin Mediated via the Nrf2/HO-1 Signaling Pathway: In Vivo and In Silico Validation. [PDF]

Pharmaceutics
Kamar SA, Magdy YM, Abuamara TMM, Sedky AA, Al-Hazani TMI, Alhelf M, Zayed ES, A Yousef T, Al-Dakhil A, Abou-Krisha MM, Almehmadi SJ, Khedr S.   +11 more
europepmc   +1 more source